Transient antibody production is suitable for small scale production for antibody screening. It allows fast and parallelized production without any need to generate producer cell lines. Moreover, transient antibody production in mammalian cells can be scaled up and generate even grams of antibodies.
Transient transfection, by definition, is different from stable cell culture. In transient transfection, DNA plasmid containing the target gene of interest is transfected into the host cells, usually HEK293 cells or CHO cells, with an efficient transfection reagent that can transport a large number of DNA plasmid through the cell membrane and into the nucleus for gene expression. Because the DNA plasmid's integration efficiency is very low, the majority of the transfected DNA remains in the cells without integrating into the chromosome, hence gene expression quickly decreases as cells divide and DNA degrades. With an engineered cell line, the cells can maintain a certain number of DNA copies in the cells for a short period of time, up to 6-12 days. The advantage of transient transfection is that it totally skipped the need for lengthy and costly stable cell line development, and hence it is highly preferable for quick and high-throughput small scale protein and antibody production.
Advancement in transient transfection technology in the last decade has made a huge impact on therapeutic antibody discovery and development. With the help of an efficient transient transfection platform, starting from antibody gene sequences, one could make sufficient quantities of monoclonal antibodies at high throughput in just a few weeks. Even 10-100 grams of high purity antibodies can be produced in just a few weeks as well. Innovation in this great technology has greatly accelerated antibody discovery and development timeline.
Sino Biological has also made significant progress in advancing transient transfection platform for protein and antibody production. We have developed HEK293 cells and CHO cells that are specifically optimized for high transient transfection efficiency and high expression yield. We've also developed and optimized serum-free media for transient transfection of HEK293 cells and CHO cells.
On the foundation of many years of antibody production experience accumulation and cutting-edge platform technologies, Sino Biological has built one of the largest capacity for high-throughput antibody production at any scale to support your antibody discovery and development. At mg level of production, hundreds of monoclonal antibodies can be processed per week. We have optimized the entire antibody production process, from antibody gene synthesis, expression vector construction, transfection plasmid production and purification, high-throughput cell culture, transient transfection, high-throughput antibody purification, and analytical support for QC testing. The technology and capability is a powerful engine for antibody product discovery and development. Nobody can afford to miss the opportunity to accelerate their antibody discovery while generating significant costing saving. Act now to contact us on how we can support your antibody discovery and development programs.
In HEK293 cell transient transfection, large quantities of DNA plasmids containing the target gene of interest are transfected into HEK293 cells, with an efficient transfection reagent that can transport DNA plasmids into the host HEK293 cells for gene expression.
Sino Biological has developed an engineered HEK293 cell line. The optimized 293 cells can maintain a certain number of DNA copies within the cells for a short period of time, up to 6-12 days. The advantage of transient transfection is that it totally skipped the need for lengthy and costly stable cell line development, and hence it is highly preferable for quick and high-throughput small scale protein and antibody production.
Sino Biological has also optimized the serum-free culture medium for optimal transfection efficiency and hence improved protein expression yield. Furthermore, Sino Biological has developed a highly efficient, room temperature stable, and cost-effective mammalian cell transfection reagent, Sinofection, that allows very efficient gene transfection, making it possible to produce large quantities of bulk proteins and bulk antibodies efficiently and at affordable costs. Multiple top multi-national pharmaceutical and biotech companies have taken advantage of our cutting-edge transient transfection platform to support their internal antibody discovery and development projects. Sino Biological offers transient transfection service to the life science community and biotech industry to accelerate basic research and antibody product discovery and development.
In the past many years, Sino Biological has produced over 6,000 recombinant proteins and over 4,600 recombinant monoclonal antibodies with our advanced HEK293 cell transient transfection platform. Our track records in transient transfection for protein and antibody production is unmatched anyway in the world. Contact us now to learn more about our HEK293 transient transfection technology and how we can help you in meeting your transient transfection needs.
In CHO (Chinese Hamster Ovary) cell transient transfection, large quantities of DNA plasmids containing the target gene of interest are transfected into the host CHO cells, with an efficient transfection reagent. Regular CHO cells have very low transfection efficiency. Sino Biological has developed an engineered CHO cell line. The optimized CHO cells have an improved transfection efficiency and can maintain a certain number of DNA copies within the cells for a short period of time, up to 6-12 days.
1. Wang, W., Brady, J., Donato, K., Peshwa, M., & Steger, K. Gram Scale Transient Antibody Production and Stable Cell Line Generation Using Flow Electroporation™ Technology.
2. Schirrmann, T., & Büssow, K. (2010). Transient production of scFv-Fc fusion proteins in mammalian cells. In Antibody engineering (pp. 387-398). Springer, Berlin, Heidelberg.
3. Jäger, V., Büssow, K., Wagner, A., Weber, S., Hust, M., Frenzel, A., & Schirrmann, T. (2013). High level transient production of recombinant antibodies and antibody fusion proteins in HEK293 cells. BMC biotechnology, 13(1), 52.